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Efficacy of chemotherapy for pancreatic cancer may be improved by tailoring it to individual chemosensitivity profiles. Identification of
nonresponders before initiation of treatment may help to avoid side effects. In this study, primary pancreatic cancer cells were
isolated from 18 patients undergoing pancreaticoduodenectomy for pancreatic cancer. Eight commonly used pancreatic cancer cell
lines were used as controls. Ex vivo chemosensitivity for gemcitabine, 5-fluorouracil, mitomycin-C, cisplatinum, oxaliplatinum,
paclitaxel and a combination of gemcitabine with oxaliplatinum or mitomycin-C was determined using a cellular ATP-based tumour
chemosensitivity assay (ATP-TCA). Quantitative real-time–polymerase chain reaction was performed to determine RNA expression
levels of genes implicated in chemoresistance. Chemosensitivity towards cytotoxic agents was highly variable in primary pancreatic
cancer cells and pancreatic cancer cell lines. ATP-TCA results for gemcitabine correlated to the tissue expression of human
equilibrative nucleoside transporter-1 (hENT1). Time to relapse in patients with gemcitabine-sensitive tumours was significantly
higher than in patients with chemoresistant pancreatic cancers (P¼0.01; 71 vs 269 days). Furthermore, time to relapse in
gemcitabine-treated patients was related to hENT1 expression (P¼0.0067). Thus, chemosensitivity testing using ATP-TCA in
pancreatic cancer is feasible and correlated with time to relapse in gemcitabine-treated patients. This suggests that ATP-TCA testing
could be used as a decision-making tool in the adjuvant treatment of pancreatic cancer.
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Chemotherapy for pancreatic cancer is only partially effective in
the adjuvant setting (Neoptolemos et al, 2004; Stocken et al, 2005;
Oettle et al, 2007). A large number of patients are resistant to the
currently used standard chemotherapeutic regimens, and the
benefit of chemotherapy is limited to a small number of patients.
Nonetheless, costs and side effects affect all patients treated. The
overall prognosis is still dismal with 5-year survival rates not
exceeding 4% (Jemal et al, 2007). Poor response to chemotherapy
may be a result of treating patients without exact knowledge of the
underlying molecular and genetic mechanisms of the disease
(Damaraju et al, 2003; Kornmann et al, 2003; Lee et al, 2005).
Chemoresistance of tumour cells can be provoked by mutations
in oncogenes (eg, K-ras), loss of tumour suppressors (eg, p53,
p16
INK4) or dysregulation of genes involved in cell cycle cell
proliferation, signal transduction, angiogenesis or apoptosis (Lee
et al, 2005; Kleeff et al, 2006). A number of studies have analysed
genes, which are directly involved in the metabolism of cytotoxic
drugs. Although the metabolisation pathways of the chemo-
therapeutic agents currently used in standard adjuvant treatment
of pancreatic cancer (gemcitabine, 5-fluorouracil and platinum
compounds) are complex, some genes that alter uptake, metabo-
lisation and catabolisation of these substances have been shown to
be associated with chemoresistance.
The first step of gemcitabine metabolism is the uptake into the
cell, which is accomplished by the human nucleoside equilibrative
transporter 1 (hENT1) (Damaraju et al, 2003; Spratlin et al, 2004;
Nakano et al, 2007; Giovannetti et al, 2006a,b). Conversion of
gemcitabine prodrug to the active diphosphate and triphosphate
metabolites is performed by deoxycytidine kinase (DCK)
(Sebastiani et al, 2006), whereas catabolism of gemcitabine
phosphates is carried out by the enzymes 50-nucleotidase and
cytidine deaminase (CDA) (Maring et al, 2005). Dihydropyrimi-
dine dehydrogenase (DPYD) (Nakayama et al, 2004; Giovannetti
et al, 2006a,b), thymidine synthase and thymidine phosphorylase
(TP) (Passantino et al, 2005) have been shown to be key enzymes
in the metabolism of 5-fluorouracil and also in the development of
chemoresistance to this drug.
Although numerous studies have addressed chemosensitivity
testing in a variety of malignancies, there are only a few studies in
pancreatic cancer. As standard chemotherapy has only limited
effects in the palliative and in the adjuvant setting, it is of Received 13 May 2008; revised 1 July 2008; accepted 1 July 2008
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specific chemotherapy. Although in vitro chemosensitivity testing
is a very attractive concept at first glance, it might not necessarily
predict in vivo responses due to a number of different factors. Sub-
populations of tumour cells may expand clonally in cell culture,
and the absence of immune cells and – particularly important – the
absence of a functional tumour microenvironment (ie, extra-
cellular matrix, blood vessels, nerves) may influence the clinical
response to a given chemotherapy (Miyamoto et al, 2004).
However, different approaches have been used to predict ex vivo
chemosensitivity of tumour cells to particular cytotoxic
agents, such as profiling of the expression of individual genes
implicated in chemoresistance (Erkan et al, 2005; Nakahira et al,
2007; Nakano et al, 2007), high-throughput analysis of many
genes (Kornmann et al, 2003; Potti et al, 2006; Chen et al,
2007) and chemosensitivity assays using primary isolated
cancer cells.
For in vitro chemosensitivity testing of cells, different assays
have been developed over time. These can roughly be divided into
two groups: clonogenic and non-clonogenic assays. Clonogenic
assays first expand tumour cells before treatment with cytotoxic
agents. In non-clonogenic assays, primary tumour cells are
exposed to chemotherapeutic drugs. The readout of the assays
might be measurement of cell proliferation, cell death or metabolic
activity. Various types of assays have been tested in a variety of
malignancies, but none so far has been evaluated in large-scale
randomised clinical trials. In this study, we used the ATP-based
tumour chemosensitivity assay (ATP-TCA), which has been shown
to be very sensitive and highly reproducible, at a low rate of failure
(Andreotti et al, 1995; Ugurel et al, 2006).
In palliative or neoadjuvant settings, the amount of cancer tissue
that can be obtained by endoscopic retrograde cholangiopancrea-
tography and fine needle aspiration is limited, which might
preclude the ATP-TCA from being used as a test system.
Alternatively, QRT–PCR (quantitative real-time polymerase chain
reaction)-driven gene expression analysis (for which the amount of
tissue needed for mRNA isolation is rather small) might be more
suitable for predicting chemosensitivity in inoperable or neo-
adjuvant-treated patients.
Thus in our study, two different in vitro techniques – ATP-TCA
and gene expression profiling – were used to analyse chemosensi-
tivity in eighteen primary human pancreatic cancer cells and eight
established pancreatic cancer cell lines. The ATP-TCA included
analysis of response of primary tumour cells and established cell
lines to gemcitabine and 5-fluorouracil. In addition, we analysed
expression of genes implicated in gemcitabine chemoresistance
(hENT1, CDA, DCK) and 5-fluorouracil chemoresistance (DPYD, TP).
PATIENTS AND METHODS
Patients and tissue sampling
Tissue samples were collected from patients undergoing pancreatic
resections for pancreatic cancer (n¼24). Primary cancer cell
isolation was technically insufficient in six patients (too few cancer
cells, bacterial contamination). Thus, 18 patients were eligible for
inclusion in our study. Table 1 shows the characteristics of the
included patients. Resected pancreatic cancer tissues were
immediately transferred to culture medium, which had been
precooled to 41C. Chemosensitivity testing was performed within
48h of sample collection. For gene expression analyses, pancreatic
tissues were immediately snap frozen at  801C and were
subsequently processed for mRNA isolation. As a control group
for gene expression analyses, normal pancreatic tissue samples
were obtained through an organ donor procurement programme
whenever there was no suitable recipient for pancreas transplanta-
tion (n¼6). The use of human tissue for the analysis was approved
by the local ethical committee (University of Heidelberg, Germany)
and written informed consent was obtained from the patients.
Chemosensitivity testing using the ATP-TCA test
Primary human pancreatic cancer cells were isolated and ATP-
TCA was performed as described previously (Andreotti et al, 1995;
Ugurel et al, 2006). Briefly, 10000–20000 tumour cells per well
were seeded in tumour cell-supporting growth medium in 96-well
microtiter plates. Chemotherapeutics were used at test drug
concentrations (TDCs) of 200, 100, 50, 25, 12.5 and 6.25% (with
100% TDC corresponding to peak plasma concentrations). The
following chemotherapeutic agents or combinations were chosen:
5-fluorouracil, gemcitabine, oxaliplatinum, cisplatinum, paclitaxel,
mitomycin C, gemcitabineþoxaliplatinum and gemcitabineþ
mitomycin C. Tests were performed in triplicate. After 7 days of
incubation, tumour cells were lysed and the amount of cellular
ATP – which correlates directly with the number of viable cells –
was determined with a luciferin/luciferase reaction. Cell prepara-
tion and ATP-TCA were performed using commercially available
reagents (TCA-100, DCS, Hamburg, Germany). Luminescence was
measured with either a LB953 luminometer (Berthold Technolo-
gies, Bad Wildbad, Germany) or a MPL2 Microplate Luminometer
(Berthold Detection Systems, Pforzheim, Germany). The above-
mentioned cytotoxic drugs have been used in the ATP-TCA test in
different ‘test drug concentrations’ (TDCs) of which 100%
correspond to the peak plasma concentration. The IC50 (inhibitory
concentration of 50%) is the concentration at which cell growth is
inhibited by 50% (which, in the ATP-TCA test, is a combination of
cell growth and cell survival); this value is calculated (as described
in the ATP-TCA test protocols as supplied by DCS diagnostics,
Hamburg, Germany) using an interpolation of two neighbouring
measurements. Test values below 50% are considered ‘sensitive’,
whereas test values above 100% are considered ‘resistant’.
Quantitative RT–PCR
Messenger-RNA isolation, cDNA preparation and QRT–PCR were
performed as described previously (Michalski et al, 2007). Primers
detecting hENT1, CDA, DCK, DPYD and TP were obtained from
Search-LC (Heidelberg, Germany). The number of specific
transcripts detected was normalised to the level of the house-
keeping gene cyclophilin-B (CPB) and expressed as the number of
target transcripts per 10000 CPB copies.
Table 1 Demographic characteristics of patients
Characteristics Number of patients
Patients enrolled 24
Patients eligible 18
Men 11
Women 7
Median age (range) 56 (40–69) years
T and N stages
T1, T2 0
T3 17
T4 1
N0 2
N1 16
Grade
21 2
36
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Differences in mRNA expression levels of hENT1, CDA, DCK,
DPYD and TP were compared using a Mann–Whitney U-test. For
correlation analysis, the Spearman rho (for primary isolated cancer
cell correlations) and Pearson (for pancreatic cancer cell line
correlations) tests were used. The survival curve of all patients and
the time to relapse/time to progress of gemcitabine-treated
patients were presented using the Kaplan–Meier method. Time
to relapse of gemcitabine-treated patients with low or high
chemosensitivity for gemcitabine was compared using a log-rank
test. The level of statistical significance was set at Po0.05.
RESULTS
Eighteen patients with resectable pancreatic adenocarcinoma were
included in the study from September 2005 to January 2006
(Table 1). At the last follow-up (March 2007), five patients had
died and thirteen patients were alive. Figure 1A shows the Kaplan–
Meier survival curve of this patient cohort. Seven patients received
first-line adjuvant chemotherapy with gemcitabine, two patients
were included into the CapRI study (for protocol, see reference
Knaebel et al, 2005), one patient received gemcitabine/capecitabine
and eight patients received no chemotherapy. Analysis of seven
patients treated with first-line gemcitabine revealed a time to
relapse of 193 days, as judged by time from initiation of
chemotherapy until radiologically detected recurrence of the
disease.
Chemosensitivity of primary human pancreatic cancer
cells
To assess chemosensitivity, the ATP-TCA test was performed on
primary (isolated) human pancreatic cancer cells of the 18
included patients. This analysis revealed a large variability in
sensitivity to the tested cytotoxic drugs (Figure 1B). Cancer cells
were resistant to platinum derivatives and mitomycin C, whereas
chemosensitivity was seen for 5-fluorouracil, gemcitabine and
paclitaxel (Figure 1B). Chemosensitivity of these cells towards
gemcitabine was increased by combining it with either oxali-
platinum or mitomycin C. As examples of the highly variable
chemosensitivity, IC50 values of 16 patients for gemcitabine and
5-fluorouracil (black and grey bars, respectively; Figure 1C; two
patients were excluded due to contamination of the primary
isolated cancer cells) are shown in comparison with the mean IC50
values of all tested cytotoxic drugs (white bars; Figure 1C).
Chemosensitivity of pancreatic cancer cell lines
A similar pattern of chemosensitivity was seen in eight standard
pancreatic cancer cell lines tested: AsPC1, BxPC3, Capan-1,
Colo357, MiaPaca-2, Panc1, Su86.86 and T3M4 (Figure 2A-D and
Figure 3A). Although these were mainly resistant towards
oxaliplatinum, cisplatinum and mitomycin C, chemosensitivity
was observed for 5-fluorouracil, gemcitabine and paclitaxel. Again,
combination therapies with gemcitabine plus oxaliplatinum or
mitomycin C rendered the cells even more sensitive than with
gemcitabine alone. However, the chemosensitivity profiles varied
considerably within these tested cell lines (Figure 2A–D). As
judged by the mean IC50 levels of all tested cytotoxic drugs, the
‘average’ pancreatic cancer cell line was chemosensitive to
5-fluorouracil, gemcitabine, paclitaxel and gemcitabine combina-
tions, whereas it showed intermediate resistance to cisplatinum
and resistance to oxaliplatinum and mitomycin C (Figure 3A).
Gene expression analysis in primary human pancreatic
cancer cells
To analyse potential associations between mRNA expression levels
of genes, which are implicated in chemoresistance, QRT–PCR was
performed using tissue specimens tested with ATP-TCA and
normal pancreas tissues as controls. This analysis (Figure 3B)
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Figure 1 (A) Kaplan–Meier survival curve of patients tested with ATP-TCA chemosensitivity assays. (B) Mean IC50 levels (% of peak plasma
concentration) of all patients in this cohort. (C) Comparison of the IC50 levels of gemcitabine (black bars) and 5-fluorouracil (grey bars) in single patients as
compared with the mean IC50 levels of all chemotherapeutic drugs (white bars).
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(P¼ns) and TP (P¼0.01) in pancreatic cancer tissues, whereas
hENT1 (P¼ns) expression was slightly reduced compared with the
normal pancreas. The TP/DPYD ratio – a marker of 5-fluorouracil
chemoresistance – was increased in primary pancreatic cancer
tissues (P¼0.008, Figure 3C).
Gene expression analysis in pancreatic cancer cell lines
To compare expression profiles of primary isolated pancreatic
cancer cells and established pancreatic cancer cell lines, gene
expression levels of hENT1, CDA, DPYD and TP were analysed in
all cell lines used before. The expression levels of these genes
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Figure 2 IC50 values (% of peak plasma concentration) of eight pancreatic cancer cell lines for (A) 5-fluorouracil and gemcitabine (5-FU, GEM; white and
black bars; (B), paclitaxel and mitomycin-C (PAC, MMC; white and black bars); (C), oxaliplatinum and cisplatinum (OX, CIS; white and black bars; (D) and
for gemcitabineþoxaliplatinum and gemcitabineþmitomycin-C (GEMþOX, GEMþMMC; white and black bars).
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Figure 3 (A) Mean IC50 levels (% of peak plasma concentration) of eight pancreatic cancer cell lines (AsPC, BxPC3, Capan1, Col357, MiaPaca-2, Panc1,
Su86.86, T3M4). (B) Expression analysis (quantitative real-time polymerase chain reaction) of genes implicated in chemoresistance (white bars: donor
pancreas; black bars: pancreatic cancer; Mann–Whitney U-test). (C) Thymidine phosphorylase (TP)/ dihydropyrimidine dehydrogenase (DPYD) ratio,
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showed expression levels of individual genes comparable with the
mean expression of the respective genes in the tested tumour
specimens (Figure 4A–D; white bars show mean tumour tissue
expression levels; black bars show expression levels in pancreatic
cancer cell lines).
Correlation analysis of chemosensitivity and gene
expression in patients
When the size of a biopsy sample is insufficient to give enough
cells for ATP-TCA, prediction of chemosensitivity using gene
expression analysis by QRT–PCR may be an option. Thus, gene
expression levels of hENT1, CDA, DCK, DPYD and TP were
analysed for correlation with the IC50 levels obtained by ATP-TCA.
As shown in Table 2, Spearman rho analysis revealed trends
towards correlation of hENT1 with gemcitabine (P¼0.099), of
CDA with paclitaxel (P¼0.066), of TP and gemcitabine or
oxaliplatinum (P¼0.068 and P¼0.069, respectively) and of the
TP/DPYD ratio and oxaliplatinum (P¼0.058). Statistically sig-
nificant correlations were observed for hENT1 and cisplatinum
(P¼0.049), for TP and gemcitabineþmitomycin C (P¼0.047), for
TP/DPYD and gemcitabine and cisplatinum (P¼0.022 and
P¼0.025, respectively). To assess whether specific gene expres-
sions can be used to predict ex vivo chemoresistance, we calculated
the mean IC50 levels for all tested chemotherapeutic drugs and
compared these with the expression levels of hENT1, CDA, DCK,
DPYD and TP for correlation. This analysis demonstrated that
hENT1 (directly) and TP expression (inversely) are related to the
‘mean’ chemosensitivity of pancreatic cancer cells (P¼0.01 and
P¼0.014, respectively). The best predictor of chemosensitivity is
the TP/DPYD ratio, which correlates highly significantly (P¼0.001)
with the mean IC50 levels of all tested chemotherapeutics.
Correlation analysis of chemosensitivity and gene
expression in cell lines
To assess whether the commonly used pancreatic cancer cell lines
reflect the results obtained with primary isolated human
pancreatic cancer cells, correlation analyses of the IC50 levels of
these cells and their gene expression profiles (hENT1, CDA, DCK,
DPYD and TP; Table 3) were performed. In contrast to the results
from primary isolated cells, the most striking observation is a
highly significant correlation of gemcitabine, gemcitabineþ
oxaliplatinum and gemcitabineþmitomycin C chemosensitivity
with the expression levels of CDA (P¼0.0003, P¼0.01 and
P¼0.002, respectively) and a trend towards a relationship between
CDA expression and the mean IC50 level of all tested drugs
T
3
M
4
S
u
8
6
.
8
6
P
a
n
c
1
M
i
a
P
a
c
a
C
o
l
o
3
5
7
C
a
p
a
n
1
B
x
P
C
3
A
s
P
C
1
C
a
n
c
e
r
 
t
i
s
s
u
e
s 0
150
300
450
600
C
o
p
i
e
s
/
1
0
 
k
 
c
o
p
i
e
s
 
c
p
b
T
3
M
4
S
u
8
6
.
8
6
P
a
n
c
1
M
i
a
P
a
c
a
C
o
l
o
3
5
7
C
a
p
a
n
1
B
x
P
C
3
A
s
P
C
1
C
a
n
c
e
r
 
t
i
s
s
u
e
s
0
250
500
750
1000
C
o
p
i
e
s
/
1
0
 
k
 
c
o
p
i
e
s
 
c
p
b
DPYD expression TP expression
T
3
M
4
S
u
8
6
.
8
6
P
a
n
c
1
M
i
a
P
a
c
a
C
o
l
o
3
5
7
C
a
p
a
n
1
B
x
P
C
3
A
s
P
C
1
C
a
n
c
e
r
 
t
i
s
s
u
e
s 0
1000
2000
3000
4000
C
o
p
i
e
s
/
1
0
 
k
 
c
o
p
i
e
s
 
c
p
b
T
3
M
4
S
u
8
6
.
8
6
P
a
n
c
1
M
i
a
P
a
c
a
C
o
l
o
3
5
7
C
a
p
a
n
1
B
x
P
C
3
A
s
P
C
1
C
a
n
c
e
r
 
t
i
s
s
u
e
s 0
4000
8000
12000
C
o
p
i
e
s
/
1
0
 
k
 
c
o
p
i
e
s
 
c
p
b
hENT1 expression CDA expression
Figure 4 (A–D) Expression of human equilibrative nucleoside transporter-1 (hENT1) (A), cytidine deaminase (CDA) (B), dihydropyrimidine
dehydrogenase (DPYD) (C) and thymidine phosphorylase (TP) (D) in eight pancreatic cancer cell lines (black bars) compared with the respective mean
expression levels in pancreatic cancer patient tissues (white bars).
Table 2 Correlation analysis: mean IC50 levels of primary isolated
pancreatic cancer cells vs gene expression
Gene expression
CTx hENT1 CDA DCK DPYD TP TP/DPYD
5-fluorouracil 0.269 0.863 0.966 0.966 0.295 0.231
gemcitabine 0.099 0.774 0.91 0.684 0.068 0.022
Oxaliplatinum 0.221 0.296 0.88 0.81 0.069 0.058
Cisplatinum 0.049 0.191 0.82 0.459 0.056 0.025
Paclitaxel 0.425 0.066 0.465 0.564 0.641 0.754
Mitomycin C 0.405 0.800 0.621 0.94 0.232 0.191
Gemcitabine+oxaliplatinum 0.169 0.725 0.599 0.982 0.076 0.220
Gemcitabine+mitomycin C 0.144 0.594 0.681 0.935 0.047 0.169
Mean IC50 levels 0.01 0.823 0.381 0.014 0.001
CDA¼cytidine deaminase; DPYD¼dihydropyrimidine dehydrogenase; hENTI¼
human equilibrative nucleoside transporter-1; TP¼thymidine phosphorylase. Bold
face: P-value significant (o0.05); italic face: P-value near significance level.
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cisplatinum chemosensitivity and DPYD expression (P¼0.004).
Ex vivo chemosensitivity predicts time to relapse in
gemcitabine-treated patients
Although only seven patients in this ATP-TCA-tested cohort
received adjuvant first-line treatment with gemcitabine, time to
relapse and chemosensitivity values were compared. In the group
of patients whose primary cancer cells were resistant towards
gemcitabine in the ATP-TCA, the median time to relapse was 71
days, whereas in the group of patients whose cancer cells exhibited
sensitivity towards gemcitabine, the median time to relapse was
269 days (P¼0.01; Figure 5A). Thus, ex vivo testing for
gemcitabine chemosensitivity using the ATP-TCA may predict
time to relapse in patients who are treated adjuvantly with
gemcitabine (Figure 5A).
Correlation analysis of gene expression profiles and
disease-free survival in gemcitabine-treated patients
For small surgical specimens and biopsies with insufficient cell
numbers for performance of the ATP-TCA, we tested whether
molecular markers (ie, expression levels of hENT1, CDA, DCK,
DPYD or TP as quantified by QRT–PCR) may be useful for
predicting chemosensitivity/chemoresistance in the palliative
setting. Expression levels of these genes were compared with the
time to relapse of the seven patients who were treated with
gemcitabine. These analyses showed that increased hENT1
expression is significantly related to the time to relapse (Spearman
r¼0.9286, P¼0.007; linear regression F¼11.48, P¼0.02;
Figure 5B). Furthermore, the TP/DPYD ratio is inversely related
to time to relapse (Spearman rho r¼ 0.75, P¼0.066; linear
regression F¼9.595, P¼0.027; Figure 5C). Thus, these markers
may be useful for predicting gemcitabine chemosensitivity for
unresectable patients with tissue specimens obtainable only
through a biopsy.
DISCUSSION
A central result of this study is that ex vivo chemosensitivity
testing using the ATP-TCA is feasible in pancreatic cancer tissue
specimens from resected patients and can be used for the potential
planning of adjuvant treatment. Test results were obtained within a
reasonable time of approximately 7 days, which allowed
chemotherapy to be started immediately after the healing process
was completed. Gene expression profiling of single genes using
QRT–PCR could be performed in a standardised way and (at least
partially) predicted the in vitro ATP-TCA response towards
gemcitabine. Interestingly, the in vitro response of primary
pancreatic cancer cells to various other nonstandard chemother-
apeutics was also highly variable in the ATP-TCA.
Pancreatic cancer cells from various patients were very
susceptible to paclitaxel, a drug exhibiting low toxicity compared
with other cytostatic agents. This indicates that paclitaxel may be
effective in pancreatic cancer when used selectively according to
the individual chemosensitivity profiles. In contrast, the majority
of isolated primary cancer cells were resistant to cisplatinum and
oxaliplatinum as well as to mitomycin C. As these chemother-
apeutics are usually associated with increased rates of toxicity (as
compared with gemcitabine and 5-fluorouracil), the lack of in vitro
cytotoxicity underlines the notion that these drugs should only be
used in selected cases and should be excluded from the standard
treatment regimens.
Although we could show that overall chemosensitivity of a set of
eight pancreatic cancer cell lines was comparable to the
chemosensitivity of isolated primary human pancreatic cancer
cells, the actual sensitivity or resistance against a specific agent
depends on the individual tumour/cell line. For in vitro
chemoresistance testing of promising anticancer agents, it should
be a prerequisite to use at least the whole set of pancreatic cancer
cell lines instead of evaluating candidates with a single cell line.
Another important finding of our study is a correlation between
in vitro chemosensitivity results and time to relapse in gemcitabine-
Table 3 Correlation analysis: mean IC50 levels of pancreatic cancer cell
lines vs gene expression
Gene expression
CTx hENT1 CDA DPYD TP TP/DPYD
5-fluorouracil 0.432 0.223 0.489 0.39 0.282
Gemcitabine 0.424 0.0003 0.988 0.679 0.49
Oxaliplatinum 0.387 0.977 0.632 0.539 0.42
Cisplatinum 0.96 0.975 0.004 0.805 0.485
Paclitaxel 0.723 0.26 0.982 0.730 0.703
Mitomycin C 0.115 0.595 0.356 0.976 0.104
gemcitabine+oxaliplatinum 0.723 0.01 0.57 0.514 0.664
Gemcitabine+mitomycin C 0.769 0.002 0.893 0.72 0.776
Mean IC50 levels 0.939 0.057 0.597 0.875 0.955
CDA¼cytidine deaminase; DPYD¼dihydropyrimidine dehydrogenase; hENTI¼
human equilibrative nucleoside transporter-1; TP¼thymidine phosphorylase. Bold
face: P-value significant (o0.05); italic face: P-value near significance level.
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Figure 5 (A) Kaplan–Meier survival curve of gemcitabine-treated, ATP-TCA-tested patients (log-rank test: chemoresistant (dotted line) vs
chemosensitive (continuous line) patients: P¼0.01). (B) Correlation analysis of human equilibrative nucleoside transporter-1 (hENT1) expression vs time to
relapse (DFS): Spearman r¼0.9286, P¼0.007; linear regression F¼11.48, P¼0.02. (C) Correlation analysis of thymidine phosphorylase (TP)/
dihydropyrimidine dehydrogenase (DPYD) ratio vs time to relapse (DFS): Spearman rho r¼ 0.75, P¼0.066; linear regression F¼9.595, P¼0.027.
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streated patients. There was not only a trend but also a significant
difference in chemotherapy response, with a much longer time to
progress in patients with chemosensitive tumour cells. The short
follow-up and the low number of patients precludes these results
from being representative of a larger patient cohort. Therefore,
large-scale trials will be necessary to define the clinical value of
test-directed chemotherapy for pancreatic cancer.
Although chemosensitivity testing has been a controversial topic
for a long time (Fruehauf and Alberts, 2005; Nagourney, 2005;
Wieand, 2005) and randomised trials are definitely needed, test-
directed chemosensitivity treatment could be offered to pancreatic
cancer patients. The decision to be made in the adjuvant setting is
not between a large number of cytotoxic drugs but rather between
gemcitabine and 5-fluorouracil (Neoptolemos et al, 2004; Stocken
et al, 2005; Oettle et al, 2007). Further studies such as ours might
reveal other chemotherapeutic agents, which would be efficient in
treatment of individual adenocarcinomas of the pancreas. In our
opinion, and in line with a recent comment on in vitro
chemosensitivity testing (Castro, 2005), test-directed chemother-
apy is justified even in a smaller cohort of patients under
randomised conditions.
Further, defining markers predictive of chemosensitivity is a
prerequisite for inoperable patients for whom only marginal
amounts of tissue are available. This might be possible by
performing gene expression profiling using QRT–PCR or micro-
array analyses. In our study, there was a correlation between
gemcitabine response and hENT1 expression, confirming what has
already been shown in the literature in retrospective studies and
in vitro experiments. However, the robustness of a single marker
seems questionable, and thus further efforts are necessary to define
a set of marker genes, which are really predictive of chemosensi-
tivity and which are not just surrogates for survival. Therefore,
controlled clinical trials using test-directed chemotherapies are
urgently needed in the palliative situation. The markers that are
found in such a patient cohort will then also be promising
candidates for predicting the response towards adjuvant che-
motherapy.
In conclusion, we have shown that in vitro chemosensitivity
testing using the ATP-TCA test or expression analysis of the drug
transporter hENT1 is feasible and may predict the response to
gemcitabine chemotherapy in pancreatic cancer. A randomised
controlled trial should be initiated to test the large-scale value of
test-directed chemotherapy in the adjuvant and palliative treat-
ment of pancreatic cancer.
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